Published in Cardiovasc Diabetol on July 30, 2014
DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res (2015) 0.93
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes. Cardiovasc Diabetol (2015) 0.92
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events. Cardiovasc Diabetol (2015) 0.85
Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK/eNOS pathway in diabetic mice. Cardiovasc Diabetol (2016) 0.84
Diabetes, Endothelial Dysfunction, and Vascular Repair: What Should a Diabetologist Keep His Eye on? Int J Endocrinol (2015) 0.83
Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study. Cardiovasc Diabetol (2016) 0.83
Long-term effect of sitagliptin on endothelial function in type 2 diabetes: a sub-analysis of the PROLOGUE study. Cardiovasc Diabetol (2016) 0.80
Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study. J Clin Endocrinol Metab (2016) 0.80
Cardiovascular efficacy of sitagliptin in patients with diabetes at high risk of cardiovascular disease: a 12-month follow-up. Cardiovasc Diabetol (2016) 0.80
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials. J Diabetes Res (2015) 0.79
Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: A meta-analysis. Sci Rep (2015) 0.79
Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study. Cardiovasc Diabetol (2016) 0.78
Effects of exenatide on postprandial vascular endothelial dysfunction in type 2 diabetes mellitus. Cardiovasc Diabetol (2015) 0.78
Vildagliptin, but not glibenclamide, increases circulating endothelial progenitor cell number: a 12-month randomized controlled trial in patients with type 2 diabetes. Cardiovasc Diabetol (2017) 0.77
Single administration of vildagliptin attenuates postprandial hypertriglyceridemia and endothelial dysfunction in normoglycemic individuals. Exp Ther Med (2014) 0.77
Effects of sitagliptin on coronary atherosclerosis evaluated using integrated backscatter intravascular ultrasound in patients with type 2 diabetes: rationale and design of the TRUST study. Heart Vessels (2015) 0.77
Impact of glycemic control with sitagliptin on the 2-year progression of arterial stiffness: a sub-analysis of the PROLOGUE study. Cardiovasc Diabetol (2016) 0.76
Acarbose Accelerates Wound Healing via Akt/eNOS Signaling in db/db Mice. Oxid Med Cell Longev (2017) 0.75
A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol (2017) 0.75
Dipeptidyl peptidase-4 inhibition: insights from the bench and recent clinical studies. Curr Opin Lipidol (2016) 0.75
Effects of sitagliptin on coronary atherosclerosis in patients with type 2 diabetes-A serial integrated backscatter-intravascular ultrasound study. Am J Cardiovasc Dis (2016) 0.75
Vildagliptin reduces plasma stromal cell-derived factor-1α in patients with type 2 diabetes compared with glimepiride. J Diabetes Investig (2016) 0.75
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3). Cardiovasc Diabetol (2017) 0.75
Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis (2009) 18.60
Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol (2002) 16.25
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med (2013) 11.34
Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet (2002) 9.48
Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med (2013) 8.74
Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA (2003) 8.47
Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab (2004) 3.65
Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia (1996) 3.62
Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J (2004) 2.96
Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol (1999) 2.75
Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care (2003) 2.50
The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care (2010) 1.60
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial. Diabetes Obes Metab (2010) 1.59
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Endocr J (2010) 1.57
Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care (1998) 1.48
Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol (2013) 1.31
Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab (2011) 1.28
Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc (2013) 1.24
Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab (2005) 1.21
CD34-positive stem cells: in the treatment of heart and vascular disease in human beings. Tex Heart Inst J (2011) 1.21
Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension (2012) 1.18
The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells. Atherosclerosis (2012) 1.17
Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol (2013) 1.17
Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. Cardiovasc Diabetol (2010) 1.08
Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest (2005) 1.03
The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci (2012) 1.01
Dipeptidyl peptidase-4 inhibitors and GLP-1 reduce myocardial infarct size in a glucose-dependent manner. Cardiovasc Diabetol (2013) 1.01
Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: a preliminary report. Cardiovasc Diabetol (2013) 0.99
Number of circulating endothelial progenitor cells as a marker of vascular endothelial function for type 2 diabetes. Vasc Med (2010) 0.97
Effects of sitagliptin beyond glycemic control: focus on quality of life. Cardiovasc Diabetol (2013) 0.97
Variability and reproducibility of flow-mediated dilatation in a multicentre clinical trial. Eur Heart J (2013) 0.95
Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med (2013) 0.94
Effect of acarbose on vascular disease in patients with abnormal glucose tolerance. Cardiovasc Drugs Ther (2008) 0.91
Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease. Am J Cardiol (2011) 0.90
Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis (2011) 0.90
Acarbose: an alpha-glucosidase inhibitor. Am J Health Syst Pharm (1996) 0.89
Relationship between flow-mediated vasodilation and cardiovascular risk factors in a large community-based study. Heart (2013) 0.88
Impact of hypertriglyceridemia on endothelial dysfunction during statin ± ezetimibe therapy in patients with coronary heart disease. Am J Cardiol (2011) 0.84
Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes. Horm Metab Res (2008) 0.83
Comparison of glycemic variability in patients with type 2 diabetes given sitagliptin or voglibose: a continuous glucose monitoring-based pilot study. Diabetes Technol Ther (2013) 0.81
Impact of ageing on the measurement of endothelium-dependent vasodilation. Pharmacol Rep (2006) 0.80
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Reconstitution of circadian oscillation of cyanobacterial KaiC phosphorylation in vitro. Science (2005) 7.28
PB2 amino acid at position 627 affects replicative efficiency, but not cell tropism, of Hong Kong H5N1 influenza A viruses in mice. Virology (2004) 5.96
Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group for Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol (2012) 4.29
Impact of heterogeneity of human peripheral blood monocyte subsets on myocardial salvage in patients with primary acute myocardial infarction. J Am Coll Cardiol (2009) 3.44
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron (2013) 3.27
Circulating monocytes and in-stent neointima after coronary stent implantation. J Am Coll Cardiol (2004) 2.95
C-reactive protein and lesion morphology in patients with acute myocardial infarction. Circulation (2003) 2.84
Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction: an intravascular ultrasound study. Circulation (2004) 2.72
Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation (2002) 2.67
Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J Clin Invest (2003) 2.39
Upregulation of TRPC1 in the development of cardiac hypertrophy. J Mol Cell Cardiol (2006) 2.17
Possible effects of vascular endothelial growth factor in the pathogenesis of chronic obstructive pulmonary disease. Am J Med (2003) 2.14
A single polymorphic amino acid on Toxoplasma gondii kinase ROP16 determines the direct and strain-specific activation of Stat3. J Exp Med (2009) 2.11
Impact of lesion length on functional significance in intermediate coronary lesions. Clin Cardiol (2012) 2.07
Direct measurement of multiple vena contracta areas for assessing the severity of mitral regurgitation using 3D TEE. JACC Cardiovasc Imaging (2012) 2.06
Increased binding of peripheral benzodiazepine receptor in Alzheimer's disease measured by positron emission tomography with [11C]DAA1106. Biol Psychiatry (2008) 2.06
Comparison of clinical characteristics and arterial remodeling by intravascular ultrasonic imaging in three age groups (< or =55, 56 to 69 and > or =70 years) of Japanese patients with acute myocardial infarction. Am J Cardiol (2007) 2.05
Identification of cardiac sarcoidosis with (13)N-NH(3)/(18)F-FDG PET. J Nucl Med (2003) 2.03
Improvement of cardiac function by increasing stimulus strength during left ventricular pacing in cardiac resynchronization therapy. Int Heart J (2014) 2.03
Cytokines produced by bone marrow cells can contribute to functional improvement of the infarcted heart by protecting cardiomyocytes from ischemic injury. Am J Physiol Heart Circ Physiol (2006) 2.01
Epicardial electrogram of the right ventricular outflow tract in patients with the Brugada syndrome: using the epicardial lead. J Am Coll Cardiol (2002) 2.01
Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction. J Am Coll Cardiol (2003) 1.95
Feasibility of noninvasive assessment of thin-cap fibroatheroma by multidetector computed tomography. JACC Cardiovasc Imaging (2009) 1.88
Influence of serotonin transporter gene polymorphism on depressive symptoms and new cardiac events after acute myocardial infarction. Am Heart J (2005) 1.86
Difference of culprit lesion morphologies between ST-segment elevation myocardial infarction and non-ST-segment elevation acute coronary syndrome: an optical coherence tomography study. JACC Cardiovasc Interv (2011) 1.82
A microRNA regulatory mechanism of osteoblast differentiation. Proc Natl Acad Sci U S A (2009) 1.80
Two cases of calcified amorphous tumor mimicking mitral valve vegetation. Circulation (2012) 1.79
Identification of protective epitopes on ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol (2003) 1.78
Impact of olmesartan on progression of coronary atherosclerosis a serial volumetric intravascular ultrasound analysis from the OLIVUS (impact of OLmesarten on progression of coronary atherosclerosis: evaluation by intravascular ultrasound) trial. J Am Coll Cardiol (2010) 1.76
Functional characterization of a trafficking-defective HCN4 mutation, D553N, associated with cardiac arrhythmia. J Biol Chem (2004) 1.75
Core protein of hepatitis C virus induces cardiomyopathy. Circ Res (2004) 1.73
Vascular endothelial growth factor-expressing mesenchymal stem cell transplantation for the treatment of acute myocardial infarction. Arterioscler Thromb Vasc Biol (2005) 1.73
Site-specific arrhythmogenesis in patients with Brugada syndrome. J Cardiovasc Electrophysiol (2003) 1.73
Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation. Circ Res (2003) 1.70
Accelerated decline of lung function in COPD patients with chronic hepatitis C virus infection: a preliminary study based on small numbers of patients. Chest (2003) 1.70
Regeneration of infarcted myocardium by intramyocardial implantation of ex vivo transforming growth factor-beta-preprogrammed bone marrow stem cells. Circulation (2005) 1.70
Time-dependent changes in plasma osteopontin levels in patients with anterior-wall acute myocardial infarction after successful reperfusion: correlation with left-ventricular volume and function. J Lab Clin Med (2005) 1.67
Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circ Cardiovasc Interv (2012) 1.65
Prevalence and distribution of sarcomeric gene mutations in Japanese patients with familial hypertrophic cardiomyopathy. Circ J (2011) 1.64
Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol (2002) 1.63
Two different coronary blood flow velocity patterns in thrombolysis in myocardial infarction flow grade 2 in acute myocardial infarction: insight into mechanisms of microvascular dysfunction. J Am Coll Cardiol (2002) 1.63
Three-dimensional geometry of the tricuspid annulus in healthy subjects and in patients with functional tricuspid regurgitation: a real-time, 3-dimensional echocardiographic study. Circulation (2006) 1.63
Assessment by optical coherence tomography of stent struts across side branch. -Comparison of bare-metal stents and drug-elution stents.-. Circ J (2010) 1.62
Assessing myocardial perfusion with the transthoracic Doppler technique in patients with reperfused anterior myocardial infarction: comparison with angiographic, enzymatic and electrocardiographic indices. Eur Heart J (2004) 1.62
Clinical implications of distal embolization during coronary interventional procedures in patients with acute myocardial infarction: quantitative study with Doppler guidewire. JACC Cardiovasc Interv (2008) 1.62
Fragmented QRS as a marker of conduction abnormality and a predictor of prognosis of Brugada syndrome. Circulation (2008) 1.62
Marked hemodynamic improvements by high-dose epoprostenol therapy in patients with idiopathic pulmonary arterial hypertension. Circ J (2010) 1.62
Beneficial effects of adaptive servo ventilation in patients with chronic heart failure. Circ J (2010) 1.60
Nitric oxide inhibits ischemia/reperfusion-induced myocardial apoptosis by modulating cyclin A-associated kinase activity. Cardiovasc Res (2003) 1.60
Black tea increases coronary flow velocity reserve in healthy male subjects. Am J Cardiol (2004) 1.59
Usefulness of automated quantitation of regional left ventricular wall motion by a novel method of two-dimensional echocardiographic tracking. Am J Cardiol (2006) 1.58
A novel KCNH2 mutation as a modifier for short QT interval. Int J Cardiol (2008) 1.57
Remote ischemic pre-conditioning alleviates contrast-induced acute kidney injury in patients with moderate chronic kidney disease. Circ J (2013) 1.57
Clinical significance of macroscopic T-wave alternans after sodium channel blocker administration in patients with Brugada syndrome. J Cardiovasc Electrophysiol (2007) 1.55
Combined vascular resection in operative resection for hilar cholangiocarcinoma: does it work or not? Surgery (2007) 1.54
Longer repolarization in the epicardium at the right ventricular outflow tract causes type 1 electrocardiogram in patients with Brugada syndrome. J Am Coll Cardiol (2008) 1.54
Multiple plaque rupture and C-reactive protein in acute myocardial infarction. J Am Coll Cardiol (2005) 1.54
Diagnostic value of epinephrine test for genotyping LQT1, LQT2, and LQT3 forms of congenital long QT syndrome. Heart Rhythm (2004) 1.53
Regional dopamine synthesis in patients with schizophrenia using L-[beta-11C]DOPA PET. Schizophr Res (2008) 1.53
Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. Circ J (2007) 1.53
Novel SCN3B mutation associated with brugada syndrome affects intracellular trafficking and function of Nav1.5. Circ J (2012) 1.52
Fragmented QRS is associated with torsades de pointes in patients with acquired long QT syndrome. Heart Rhythm (2010) 1.52
Cellular expression of integrin-beta 1 is of critical importance for inducing therapeutic angiogenesis by cell implantation. Cardiovasc Res (2005) 1.52
Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol (2004) 1.51
Targeted disruption of LIG-1 gene results in psoriasiform epidermal hyperplasia. FEBS Lett (2002) 1.51
Spontaneous electrocardiogram alterations predict ventricular fibrillation in Brugada syndrome. Heart Rhythm (2011) 1.51
A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). JACC Cardiovasc Interv (2009) 1.50
Role of microvascular permeability on physiologic differences in asthma and eosinophilic bronchitis. Am J Respir Crit Care Med (2004) 1.50
Identification and physiological activity of survival factor released from cardiomyocytes during ischaemia and reperfusion. Cardiovasc Res (2008) 1.49
Bedside assessment of myocardial viability using transmural strain profile in patients with ST elevation myocardial infarction: comparison with cardiac magnetic resonance imaging. J Am Soc Echocardiogr (2009) 1.49
Altered coronary vasomotor function in young patients with systemic lupus erythematosus. Arthritis Rheum (2007) 1.49
The role of echocardiography in predicting responders to cardiac resynchronization therapy. Circ J (2011) 1.49
Pravastatin improves remodeling and cardiac function after myocardial infarction by an antiinflammatory mechanism rather than by the induction of angiogenesis. Ann Thorac Surg (2006) 1.49
Effects of pranlukast administration on vascular endothelial growth factor levels in asthmatic patients. Chest (2004) 1.48
Effects of carvedilol on oxidative stress in polymorphonuclear and mononuclear cells in patients with essential hypertension. Am J Med (2004) 1.47
Comparison of contrast media and low-molecular-weight dextran for frequency-domain optical coherence tomography. Circ J (2012) 1.47
Mitral regurgitation associated with mitral annular dilation in patients with lone atrial fibrillation: an echocardiographic study. Echocardiography (2009) 1.46
The reduction of hemodynamic loading assists self-regeneration of the injured heart by increasing cell proliferation, inhibiting cell apoptosis, and inducing stem-cell recruitment. J Thorac Cardiovasc Surg (2007) 1.46
Acute-phase glucose fluctuation is negatively correlated with myocardial salvage after acute myocardial infarction. Circ J (2013) 1.46
Different determinants of residual tricuspid regurgitation after tricuspid annuloplasty: comparison of atrial septal defect and mitral valve prolapse. J Am Soc Echocardiogr (2009) 1.46
Prognosis of vulnerable plaque on computed tomographic coronary angiography with normal myocardial perfusion image. Eur Heart J Cardiovasc Imaging (2013) 1.46
Advantage of next-generation frequency-domain optical coherence tomography compared with conventional time-domain system in the assessment of coronary lesion. Catheter Cardiovasc Interv (2010) 1.44